2 weeks Ago By ABMN Staff
Theratechnologies Inc. ( NASDAQ:THTX – Free Report ) – Investment analysts at Leede Financial decreased their FY2026 earnings per share estimates for Theratechnologies in a research report issued on Monday, April 14th. Leede Financial analyst D.
Loe now expects that the company will post earnings per share of $0.12 for the year, down from their prior estimate of $0.15.
The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2027 earnings at $0.
20 EPS. Other equities analysts have also recently issued reports about the company. Research Capitl upgraded Theratechnologies to a “strong-buy” rating in a research report on Friday, February 14th.
Jones Trading raised Theratechnologies from a “hold” rating to a “strong-buy” rating in a report on Friday, April 11th. Theratechnologies Trading Down 3.4 % Shares of NASDAQ:THTX opened at $2.
57 on Tuesday. Theratechnologies has a twelve month low of $1.08 and a twelve month high of $3.
13. The firm has a market cap of $118.17 million, a P/E ratio of -25.
70 and a beta of 1.11. The company has a 50 day moving average of $1.
67 and a 200-day moving average of $1.54. Institutional Investors Weigh In On Theratechnologies A number of institutional investors and hedge funds have recently modified their holdings of the stock.
Harbour Investments Inc. lifted its holdings in shares of Theratechnologies by 20.0% during the fourth quarter.
Harbour Investments Inc. now owns 87,772 shares of the company’s stock valued at $159,000 after purchasing an additional 14,655 shares during the last quarter. Raymond James Financial Inc.
purchased a new stake in Theratechnologies during the fourth quarter valued at about $27,000. Bank of America Corp DE boosted its holdings in shares of Theratechnologies by 1,416.7% in the fourth quarter.
Bank of America Corp DE now owns 16,487 shares of the company’s stock worth $30,000 after buying an additional 15,400 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of Theratechnologies in the fourth quarter worth approximately $33,000.
Finally, Wealthspire Advisors LLC raised its holdings in shares of Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after acquiring an additional 20,000 shares during the period.
Theratechnologies Company Profile ( Get Free Report ) Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Featured Stories Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.
com's FREE daily email newsletter ..
